Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -367.93% is 14% above its 4-year average of -427.52%, near the high end of its 4-year range (-1990.37%–1.58%).
64.84% above its 12-month average of -1046.51%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -41.34%.
RETURN ON ASSETS (ROA)
-367.93%
RETURN ON ASSETS (ROA) AVG TTM
-1046.51%
RETURN ON ASSETS (ROA) AVG 3Y
-534.79%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+64.84%
CURRENT VS 3Y AVG
+31.20%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.73%
median of 726 covered companies
CURRENT VS SECTOR MEDIAN
-1097.49%
vs the sector median at left
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.17M
Return on Assets (ROA)
-367.93%
TTM Avg
-1046.51%
3Y Avg
-534.79%
5Y Avg
N/A
Market Cap
$5.17M
Return on Assets (ROA)
-1300.98%
TTM Avg
-1108.45%
3Y Avg
-604.75%
5Y Avg
-486.62%
Market Cap
$5.17M
Return on Assets (ROA)
-71.72%
TTM Avg
-29.50%
3Y Avg
-8.92%
5Y Avg
-8.92%
Market Cap
$5.24M
Return on Assets (ROA)
-123.63%
TTM Avg
-110.43%
3Y Avg
-77.11%
5Y Avg
-65.55%
Market Cap
$5.24M
Return on Assets (ROA)
-104.10%
TTM Avg
-116.11%
3Y Avg
-102.15%
5Y Avg
-84.67%
Market Cap
$5.29M
Return on Assets (ROA)
-106.49%
TTM Avg
-259.99%
3Y Avg
-586.63%
5Y Avg
-434.16%
Market Cap
$5.04M
Return on Assets (ROA)
-98.17%
TTM Avg
-154.79%
3Y Avg
-120.06%
5Y Avg
-94.26%
Market Cap
$5.32M
Return on Assets (ROA)
-30.94%
TTM Avg
-24.01%
3Y Avg
-19.50%
5Y Avg
-23.56%
Market Cap
$4.82M
Return on Assets (ROA)
-161.71%
TTM Avg
-175.21%
3Y Avg
-164.83%
5Y Avg
-138.13%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.17M | -367.93% | -1046.51% | -534.79% | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.17M | -1300.98% | -1108.45% | -604.75% | -486.62% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.17M | -71.72% | -29.50% | -8.92% | -8.92% |
| Pulmatrix, Inc. (PULM)vs › | $5.24M | -123.63% | -110.43% | -77.11% | -65.55% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -104.10% | -116.11% | -102.15% | -84.67% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | -106.49% | -259.99% | -586.63% | -434.16% |
| Imunon, Inc. (IMNN)vs › | $5.04M | -98.17% | -154.79% | -120.06% | -94.26% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -30.94% | -24.01% | -19.50% | -23.56% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.82M | -161.71% | -175.21% | -164.83% | -138.13% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.66M | -54.95% | -72.19% | -72.80% | -69.14% |
ROA
-367.9%
ROE
-4165.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -1990.37% |
| 2024-12-31 | -102.66% |
| 2023-12-31 | -27.24% |
| 2022-12-31 | -18.90% |
| 2021-12-31 | 1.58% |
